Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Blerim Myftiu; Zylfije Hundozi; Faton Sermaxhaj; Afrim Blyta; Nexhmedin Shala; Fisnik Jashari; Hasime Qorraj Bytyqi; Ekrem Hyseni; Ilir Kurtishi

doi:10.12659/MSM.937856

31 August 2022 : Clinical Research

Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Blerim Myftiu^12ABCDEFG*, Zylfije Hundozi^12ACDF, Faton Sermaxhaj^3ABD, Afrim Blyta^1ACDF, Nexhmedin Shala^12CD, Fisnik Jashari^12C, Hasime Qorraj Bytyqi^4CDF, Ekrem Hyseni^3BC, Ilir Kurtishi^3BC

DOI: 10.12659/MSM.937856

Med Sci Monit 2022; 28:e937856

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Chemotherapy protocols.

Treatment regimen	Number	Age (Mean±SD)
Platinum only	2	61±1.4
Platinum + Taxane	20	62.5±10.7
Platinum + Antimetabolites	53	61.45±8.4
Platinum + Taxane + Doxorubicin	1	55
Platinum + Taxane + Antimetabolites	1	58
Platinum + Doxorubicin + Antimetabolites	1	50
Platinum + Dacarbazine	1	55
Platinum + Etoposide	4	44.5±19.3
Taxane + Antimetabolites	6	58.6±8.0
Taxane + Doxorubicin	2	70±7.0
Taxane + Doxorubicin + Alkylating	20	55±13.1
Irinotecan + Antimetabolites	3	65.6±4.6
Alkilating + Doxorubicin	4	57.7±13.4
Doxorubicin + Vinblastin + Dacarbazine + Bleomycin	1	26
Taxane + Antimetabolites + Etoposide	1	51

SD – standard deviation.

Back to the Article

Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Your Privacy